PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.

Launched by JULES BORDET INSTITUTE · Sep 26, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a special type of imaging called PSMA-PET/CT to understand how a specific protein, known as PSMA, behaves in women with a type of breast cancer called triple-negative breast cancer (TNBC) that is spreading and hard to treat. The goal is to see if this imaging can help identify patients who might benefit from a new type of treatment using a radioactive substance called Lutetium-177, which targets PSMA. The study is currently recruiting participants who are women aged 18 and older with confirmed progressive metastatic TNBC.

To be considered for this trial, participants will need to provide written consent and must have measurable cancer that has been confirmed through recent imaging tests. Participants should not be pregnant or breastfeeding and should not have any other active cancers or recent treatments with other investigational drugs. Those who join the study can expect to undergo PSMA-PET/CT imaging before starting their next cancer treatment, helping researchers understand if this approach can lead to new treatment options for challenging cases of TNBC.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent in accordance with institutional guidelines and obtained prior to any study procedure
• • Women with ≥ 18 years-old
• • Eastern Cooperative Oncology Group Performance Status of 0 to 2
• • Confirmed diagnosis of progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET/CT (performed within 2 weeks) or Brain MRI in case of progressive brain metastases (performed within 4 weeks) prior to PSMA PET/CT.
• • Radiolabelled PSMA PET/CT has to be performed before the next treatment line initiation
• Exclusion Criteria:
• • Pregnant or lactating patients
• • Other active neoplastic disease
• • Treatment by another molecule that is the object of investigation within 30 days
• • Skin only metastatic disease
• • Patients with a significant medical, neuro-psychiatric, or surgical condition, which, in the investigator's opinion, may interfere with completion of the study